Literature DB >> 26179099

Assessment of litter prevalence of Mycoplasma hyopneumoniae in preweaned piglets utilizing an antemortem tracheobronchial mucus collection technique and a real-time polymerase chain reaction assay.

Frédéric Vangroenweghe1, Locke Karriker2, Rodger Main2, Eric Christianson2, Thomas Marsteller2, Kristin Hammen2, Jessica Bates2, Paul Thomas2, Josh Ellingson2, Karen Harmon2, Sarah Abate2, Kimberly Crawford2.   

Abstract

The swine industry currently lacks validated antemortem methods of detecting baseline herd prevalence of Mycoplasma hyopneumoniae. The focus of our study was to evaluate alternative antemortem detection techniques and to determine baseline litter prevalence in preweaned pig populations utilizing the selected technique and a real-time polymerase chain reaction (qPCR) assay. Preliminary data was analyzed on weaned piglets with evidence of respiratory disease (n = 32). Five sample types (antemortem nasal swab, tracheobronchial mucus, postmortem deep airway swab, bronchoalveolar lavage, and lung tissue) were collected from each pig. Individual samples were tested for M. hyopneumoniae using qPCR. Compared to nasal swabs, tracheobronchial mucus demonstrated higher test sensitivity (P < 0.0001). Tracheobronchial mucus was collected from apparently healthy preweaned piglets (n = 1,759; sow farms 1-3) and preweaned piglets exhibiting signs of respiratory disease (n = 32; sow farm 4), ranging in age from 12 to 25 days. Samples from sow farms 1-3 were pooled into 2 groups of 5 per litter (n = 360 pools from 180 litters), and qPCR was utilized to analyze each pool. A qPCR-positive result, threshold cycle <37, from either pool designated the litter positive for M. hyopneumoniae. Two out of 180 litters revealed a positive result (1.1%). Individual qPCR assays were run on the samples collected from sow farm 4. Five out of 30 samples revealed a positive result (16.7%). Tracheobronchial mucus collection in combination with qPCR is a sensitive antemortem sampling technique that can be used to estimate the prevalence of M. hyopneumoniae in preweaned pigs, thus providing insight into the infection dynamics across the entire farrow-to-finish process.
© 2015 The Author(s).

Entities:  

Keywords:  Mucus; Mycoplasma hyopneumoniae; pigs; prevalence; sampling; tracheobronchial

Mesh:

Year:  2015        PMID: 26179099     DOI: 10.1177/1040638715595062

Source DB:  PubMed          Journal:  J Vet Diagn Invest        ISSN: 1040-6387            Impact factor:   1.279


  5 in total

1.  Dynamics of Mycoplasma hyopneumoniae seroconversion and infection in pigs in the three main production systems.

Authors:  Enrico Giacomini; Nicola Ferrari; Alessandra Pitozzi; Michela Remistani; Daniele Giardiello; Dominiek Maes; Giovanni Loris Alborali
Journal:  Vet Res Commun       Date:  2016-05-04       Impact factor: 2.459

2.  Microbiome overview in swine lungs.

Authors:  Franciele Maboni Siqueira; Esteban Pérez-Wohlfeil; Fabíola Marques Carvalho; Oswaldo Trelles; Irene Silveira Schrank; Ana Tereza Ribeiro Vasconcelos; Arnaldo Zaha
Journal:  PLoS One       Date:  2017-07-18       Impact factor: 3.240

3.  Use of trachea-bronchial swab qPCR testing to confirm Mycoplasma hyopneumoniae seropositivity in an SPF breeding herd.

Authors:  Frédéric Vangroenweghe; Eveline Willems; Jiří Malášek; Olivier Thas; Dominiek Maes
Journal:  Porcine Health Manag       Date:  2018-06-01

4.  Development of an indirect ELISA for detection of anti-Mycoplasma hyopneumoniae IgG in naturally infected pathogen-induced convalescent sera.

Authors:  Yaqin Tian; Zuobo Xu; Yukang Wen; Mei Yang; Yaru Ning; Zhaodi Wang; Honglei Ding
Journal:  BMC Vet Res       Date:  2021-03-16       Impact factor: 2.741

5.  Development of an ELISA for distinguishing convalescent sera with Mycoplasma hyopneumoniae infection from hyperimmune sera responses to bacterin vaccination in pigs.

Authors:  Honglei Ding; Yukang Wen; Zuobo Xu; Bingqian Zhou; Chaker Tlili; Yaqin Tian; Zhaodi Wang; Yaru Ning; Jiuqing Xin
Journal:  Vet Med Sci       Date:  2021-05-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.